ChromaDex (CDXC) 10-Q 12 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 03, 2015	Nov. 11, 2015
Document And Entity Information
Entity Registrant Name	ChromaDex Corp.
Entity Central Index Key	1,386,570
Document Type	10-Q
Document Period End Date	Oct. 3, 2015
Amendment Flag	false
Current Fiscal Year End Date	--01-02
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		109,114,247
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Oct. 03, 2015	Jan. 03, 2015
Current Assets
Cash	$ 4,708,642	$ 3,964,750
Trade receivables, less allowance for doubtful accounts and returns, October 3, 2015 $43,000; January 3, 2015 $38,000	3,784,541	1,906,709
Inventories	4,163,628	3,734,341
Prepaid expenses and other assets	377,469	292,891
Total current assets	13,034,280	9,898,691
Leasehold Improvements and Equipment, net	1,581,961	1,264,660
Deposits	59,040	57,435
Intangible assets, net	371,325	296,061
Total assets	15,046,606	11,516,847
Current Liabilities
Accounts payable	3,560,569	3,451,608
Accrued expenses	1,215,166	853,685
Current maturities of loan payable	598,837	223,358
Current maturities of capital lease obligations	216,551	148,278
Customer deposits and other	236,828	234,435
Deferred rent, current	52,914	69,456
Total current liabilities	5,880,865	4,980,820
Loan payable, less current maturities, net	4,226,414	1,977,113
Capital lease obligations, less current maturities	500,128	423,015
Deferred rent, less current	103,461	137,508
Total Liabilities	10,710,868	7,518,456
Stockholders' Equity
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding October 3, 2015 106,319,606 and January 3, 2015 105,271,058 shares	106,320	105,271
Additional paid-in capital	45,098,163	43,417,442
Accumulated deficit	(40,868,745)	(39,524,322)
Total stockholders' equity	4,335,738	3,998,391
Total liabilities and stockholders' equity	$ 15,046,606	$ 11,516,847

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Oct. 03, 2015	Jan. 03, 2015
Statement of Financial Position [Abstract]
Trade receivables, less allowance for doubtful accounts and returns	$ 43,000	$ 38,000
Common Stock, Par Value Per Share	$ .001	$ .001
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	106,319,606	105,271,058
Common Stock, Shares, Outstanding	106,319,606	105,271,058

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations 3 Months Ended (Unaudited) - USD ($)	3 Months Ended				9 Months Ended
	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014
Income Statement [Abstract]
Sales, net	$ 6,287,309			$ 4,139,710	$ 17,649,660	$ 11,070,002
Cost of sales	3,805,679			2,616,764	10,769,714	7,163,282
Gross profit	2,481,630			1,522,946	6,879,946	3,906,720
Operating expenses:
Sales and marketing	550,878			518,662	1,776,403	1,554,777
General and administrative	1,753,622			1,651,718	6,016,557	6,458,027
Operating expenses	2,304,500			2,170,380	7,792,960	8,034,347
Operating income (loss)	177,130			(647,434)	(913,014)	(4,127,627)
Nonoperating income (expense):
Interest income	976			230	2,339	1,175
Interest expense	(181,822)			(12,449)	(433,748)	(34,359)
Nonoperating expenses	(180,846)			(12,219)	(431,409)	(33,184)
Net loss	$ (3,716)	$ (315,192)	$ (1,025,515)	$ (659,653)	$ (1,344,423)	$ (4,160,811)
Basic and Diluted loss per common share	$ 0			$ (.01)	$ (0.01)	$ (0.04)
Basic and Diluted weighted average common shares outstanding	107,442,916			106,610,400	107,350,469	106,290,782

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations 9 Months Ended (Unaudited) - USD ($)	3 Months Ended				9 Months Ended
	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014
Income Statement [Abstract]
Sales, net	$ 6,287,309			$ 4,139,710	$ 17,649,660	$ 11,070,002
Cost of sales	3,805,679			2,616,764	10,769,714	7,163,282
Gross profit	2,481,630			1,522,946	6,879,946	3,906,720
Operating expenses:
Sales and marketing	550,878			518,662	1,776,403	1,554,777
General and administrative	1,753,622			1,651,718	$ 6,016,557	6,458,027
Loss from investment in affiliate						21,543
Operating expenses	2,304,500			2,170,380	$ 7,792,960	8,034,347
Operating income (loss)	177,130			(647,434)	(913,014)	(4,127,627)
Nonoperating income (expense):
Interest income	976			230	2,339	1,175
Interest expense	(181,822)			(12,449)	(433,748)	(34,359)
Nonoperating expenses	(180,846)			(12,219)	(431,409)	(33,184)
Net loss	$ (3,716)	$ (315,192)	$ (1,025,515)	$ (659,653)	$ (1,344,423)	$ (4,160,811)
Basic and Diluted loss per common share	$ 0			$ (.01)	$ (0.01)	$ (0.04)
Basic and Diluted weighted average common shares outstanding	107,442,916			106,610,400	107,350,469	106,290,782

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Oct. 03, 2015	Sep. 27, 2014
Cash Flows From Operating Activities
Net loss	$ (1,344,423)	$ (4,160,811)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of leasehold improvements and equipment	209,754	161,712
Amortization of intangibles	32,236	24,826
Share-based compensation expense	1,656,504	2,467,720
Allowance for doubtful trade receivables	$ 5,429	24,190
Gain on exchange of equipment		$ (17,301)
Loss from disposal of equipment	$ 19,643
Loss from investment in affiliate		$ 21,543
Non-cash financing costs	$ 139,780
Changes in operating assets and liabilities:
Trade receivables	$ (1,883,261)	$ (1,714,035)
Other receivable		215,000
Inventories	$ (429,287)	(81,961)
Prepaid expenses and other assets	(86,183)	(87,068)
Accounts payable	108,961	967,229
Accrued expenses	361,481	201,147
Customer deposits and other	2,393	(320,127)
Deferred rent	(50,589)	(36,732)
Net cash used in operating activities	(1,257,562)	(2,334,668)
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment	(242,765)	(53,428)
Purchases of intangible assets	$ (107,500)	(90,000)
Proceeds from sale of equipment		1,356
Proceeds from investment in affiliate		1,092,500
Net cash provided by (used in) investing activities	$ (350,265)	950,428
Cash Flows From Financing Activities
Proceeds from exercise of stock options	25,266	$ 449,158
Proceeds from loan payable	2,500,000
Payment of debt issuance cost	(15,000)
Principal payments on capital leases	(158,547)	$ (122,496)
Net cash provided by financing activities	2,351,719	326,662
Net increase (decrease) in cash	743,892	(1,057,578)
Cash Beginning of Period	3,964,750	2,261,336
Cash Ending of Period	4,708,642	1,203,758
Supplemental Disclosures of Cash Flow Information
Cash payments for interest	293,968	34,359
Supplemental Schedule of Noncash Investing Activity
Capital lease obligation incurred for the purchase of equipment	303,933	322,802
Retirement of fully depreciated equipment - cost	8,181	56,110
Retirement of fully depreciated equipment - accumulated depreciation	$ (8,181)	(56,110)
Supplemental Schedule of Noncash Operating Activity
Stock issued to settle outstanding payable balance		137,494
Supplemental Schedule of Noncash Share-based Compensation
Changes in prepaid expenses associated with share-based compensation		$ 55,631

Condensed Consolidated Stateme7

Condensed Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Shares at Jan. 03, 2015	105,271,058
Beginning Balance, Amount at Jan. 03, 2015	$ 105,271	$ 43,417,442	$ (39,524,322)	$ 3,998,391
Share-based compensation, Shares	210,000
Share-based compensation, Amount	$ 210	715,699		$ 715,909
Vested restricted stock, shares	506,000
Vested restricted stock, Amount	$ 506	$ (506)
Net loss			$ (1,025,515)	$ (1,025,515)
Ending Balance, Shares at Apr. 04, 2015	105,987,058
Ending Balance, Amount at Apr. 04, 2015	$ 105,987	$ 44,132,635	(40,549,837)	3,688,785
Beginning Balance, Shares at Jan. 03, 2015	105,271,058
Beginning Balance, Amount at Jan. 03, 2015	$ 105,271	43,417,442	(39,524,322)	$ 3,998,391
Exercise of stock options, Shares
Net loss				$ (1,344,423)
Ending Balance, Shares at Oct. 03, 2015	106,319,606
Ending Balance, Amount at Oct. 03, 2015	$ 106,320	45,098,163	(40,868,745)	4,335,738
Beginning Balance, Shares at Apr. 04, 2015	105,987,058
Beginning Balance, Amount at Apr. 04, 2015	$ 105,987	44,132,635	$ (40,549,837)	3,688,785
Exercise of stock options, Shares	22,745
Exercise of stock options, Amount	$ 23	15,578		15,601
Share-based compensation, Shares	125,000
Share-based compensation, Amount	$ 125	507,143		$ 507,268
Vested restricted stock, shares	156,000
Vested restricted stock, Amount	$ 156	$ (156)
Net loss			$ (315,192)	$ (315,192)
Ending Balance, Shares at Jul. 04, 2015	106,290,803
Ending Balance, Amount at Jul. 04, 2015	$ 106,291	$ 44,655,200	$ (40,865,029)	3,896,462
Exercise of stock options, Shares	12,803
Exercise of stock options, Amount	$ 13	9,652		9,665
Share-based compensation, Shares
Share-based compensation, Amount		433,327		$ 433,327
Vested restricted stock, shares	16,000
Vested restricted stock, Amount	$ 16	$ (16)
Net loss			$ (3,716)	$ (3,716)
Ending Balance, Shares at Oct. 03, 2015	106,319,606
Ending Balance, Amount at Oct. 03, 2015	$ 106,320	$ 45,098,163	$ (40,868,745)	$ 4,335,738

Interim Financial Statements

Interim Financial Statements	9 Months Ended
	Oct. 03, 2015
Interim Financial Statements
Note 1. Interim Financial Statements	The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of October 3, 2015 and results of operations and cash flows for the three and nine months ended October 3, 2015 and September 27, 2014. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended January 3, 2015 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2015. Operating results for the nine months ended October 3, 2015 are not necessarily indicative of the results to be achieved for the full year ending on January 2, 2016. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The balance sheet at January 3, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Nature of Business and Liquidit

Nature of Business and Liquidity	9 Months Ended
	Oct. 03, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Note 2. Nature of Business and Liquidity	Nature of business Liquidity With the capital raise described above, we anticipate that our current cash and cash equivalents on hand and cash generated from operations will be sufficient meet our projected operating plans through at least December 31, 2016. We may, however, require additional funds, either through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Oct. 03, 2015
Accounting Policies [Abstract]
Note 3. Significant Accounting Policies	Basis of presentation Changes in accounting principle: The Company early adopted the amendments in this ASU effective as of April 4, 2015. As of October 3, 2015 and January 3, 2015, the Company had unamortized debt issuance costs of $75,264 and $91,361, respectively. The Company had previously presented the debt issuance costs as other noncurrent assets in its consolidated balance sheet as of January 3, 2015 in the Company’s Annual Report on Form 10-K filed with the Commission on March 19, 2015. The early adoption has resulted in adjustments to the Company’s consolidated balance sheet as of January 3, 2015, by reclassifying the debt issuance costs as a direct deduction from the carrying amount of the debt liability. Below are the effects of the change on the consolidated balance sheet as of January 3, 2015. ChromaDex Corporation and Subsidiaries Condensed Consolidated Balance Sheet January 3, 2015 Previously As Reported Adjustments Adjusted Assets Current Assets $ 9,898,691 $ - $ 9,898,691 Leasehold Improvements and Equipment, net 1,264,660 - 1,264,660 Other Noncurrent Assets 444,857 (91,361 ) 353,496 Total assets $ 11,608,208 $ (91,361 ) $ 11,516,847 Liabilities and Stockholders' Equity Current Liabilities $ 4,980,820 $ - $ 4,980,820 Loan payable, less current maturities, net 2,068,474 (91,361 ) 1,977,113 Capital lease obligations, less current maturities 423,015 - 423,015 Deferred rent, less current 137,508 - 137,508 Total liabilities 7,609,817 (91,361 ) 7,518,456 Total stockholders' equity 3,998,391 - 3,998,391 Total liabilities and stockholders' equity $ 11,608,208 $ (91,361 ) $ 11,516,847 Inventories October 3, 2015 January 3, 2015 Natural product fine chemicals $ 1,695,326 $ 1,760,305 Bulk ingredients 3,163,302 2,298,036 4,858,628 4,058,341 Less valuation allowance 695,000 324,000 $ 4,163,628 $ 3,734,341

Loss Per Share Applicable to Co

Loss Per Share Applicable to Common Stockholders	9 Months Ended
	Oct. 03, 2015
Loss Per Share Applicable To Common Stockholders
Note 4. Loss Per Share Applicable to Common Stockholders	The following table sets forth the computations of loss per share amounts applicable to common stockholders for the three and nine months ended October 3, 2015 and September 27, 2014: Three Months Ended Nine Months Ended Oct. 3, 2015 Sept. 27, 2014 Oct. 3, 2015 Sept. 27, 2014 Net loss $ (3,716 ) $ (659,653 ) $ (1,344,423 ) $ (4,160,811 ) Basic and diluted loss per common share $ (0.00 ) $ (0.01 ) $ (0.01 ) $ (0.04 ) Weighted average common shares outstanding (1): 107,442,916 106,610,400 107,350,469 106,290,782 Potentially dilutive securities (2): Stock options 15,839,603 13,890,766 15,839,603 13,890,766 Warrants 469,020 - 469,020 - Convertible Debt 773,395 - 773,395 - (1) Includes 1,132,241 and 1,676,175 weighted average nonvested shares of restricted stock for the three months ended October 3, 2015 and September 27, 2014, respectively, and 1,305,605 and 1,606,380 weighted average nonvested shares of restricted stock for the nine months ended October 3, 2015 and September 27, 2014, respectively, which are participating securities that feature voting and dividend rights. (2) Excluded from the computation of loss per share as their impact is antidilutive.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	9 Months Ended
	Oct. 03, 2015
Leasehold Improvements And Equipment
Note 5. Leasehold Improvements and Equipment	Leasehold improvements and equipment consisted of the following: October 3, 2015 January 3, 2015 Laboratory equipment $ 3,577,132 $ 3,151,748 Leasehold improvements 513,453 495,240 Computer equipment 379,806 329,737 Furniture and fixtures 15,678 13,039 Office equipment 21,547 7,877 Construction in progress 21,561 68,141 4,529,177 4,065,782 Less accumulated depreciation 2,947,216 2,801,122 $ 1,581,961 $ 1,264,660 Depreciation expense on leasehold improvements and equipment included in the consolidated statement of operations for the nine months ended October 3, 2015 and September 27, 2014 was approximately $210,000 and $162,000, respectively.

Loan Payable

Loan Payable	9 Months Ended
	Oct. 03, 2015
Debt Disclosure [Abstract]
Note 6. Loan Payable	On June 17, 2015, the Company and Hercules Technology II, L.P entered into Amendment No. 1 (the “Amendment”) to the Loan and Security Agreement entered into by the parties on September 29, 2014 (the “Agreement”). The terms of the Agreement provided the Company with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing. The remaining $2.5 million of the term loan was to be drawn down in part or in full at our option at any time but no later than July 31, 2015. The first advance and second advance, if any, were to be repaid in equal monthly installments through the loan’s maturity on April 1, 2018, following an initial interest-only period that was to conclude on October 31, 2015. Pursuant to the Amendment, the parties agreed that the interest only period shall be extended to March 31, 2016, provided however that if the Company’s consolidated revenue is equal to or greater than $11.5 million for the six months ending December 31, 2015, then the interest-only period shall be extended to June 30, 2016. The maturity date remains unchanged at April 1, 2018 and any remaining principal balance of the loan and all unpaid interest shall be due on the maturity date. The Amendment became effective on June 18, 2015 upon the funding of the full amount of the $2.5 million second advance and payment of a nonrenewable facility fee of $15,000 to the Agent. The second advance of $2.5 million is treated as if the Company entered into a separate loan. The facility fee of $15,000 is treated as debt issuance costs and are being amortized as interest expense using the effective interest method over the term of the loan. There is also additional $93,750 end of term charge the Company will pay, which is 3.75% of the $2.5 million drawn. The end of term charge is being accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company determined that the amended terms of the first advance of $2.5 million on September 29, 2014 were not substantially different from the original terms. The Company therefore did not apply debt extinguishment treatment, but rather accounted for prospectively as yield adjustments, based on the revised terms. Loan payable as of October 3, 2015 consists of the following: Principal amount payable for following years ending December 2015 $ - 2016 905,393 2017 1,945,650 2018 2,148,957 Total principal payments 5,000,000 Accrued end of term charge 49,551 Total loan payable 5,049,551 Less unamortized debt issuance costs and debt discount 224,300 Less current portion 598,837 Loan payable – long term $ 4,226,414 The total interest expenses related to the term loan, including cash interest payments, the amortizations of debt issuance costs and debt discount, and the accrual of the end of term charge were approximately $166,000 and $387,000 for the three and nine months ended October 3, 2015. For the three and nine months ended September 27, 2014, the Company did not have any interest expense related to loan payable as the Company did not have any outstanding balance.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Oct. 03, 2015
Share-based Compensation
Note 7. Share-Based Compensation	7A. Employee Share-Based Compensation Stock Option Plans Service Period The majority of options granted by the Company feature service conditions. Accordingly, these options vest ratably over specified The following table summarizes our stock option activity during Weighted Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term Value Outstanding at January 3, 2015 12,723,601 $ 1.13 7.00 Options Granted 2,051,685 1.22 10.00 Options Classification from Employee to Non-Employee (1,542,071 ) 0.93 Options Exercised (35,548 ) 0.71 Options Forfeited (150,586 ) 1.16 Outstanding at October 3, 2015 13,047,081 $ 1.17 6.64 $ 2,389,000 Exercisable at October 3, 2015 9,793,365 $ 1.16 5.84 $ 2,061,000 The aggregate intrinsic values in the table Certain employees who were previously classified as employees under the share-based compensation plan have been reclassified to non-employees during the nine months ended October 3, 2015 as they became consultants. There was no impact on accounting as the options were fully vested. The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted to employees during the nine months ended October 3, 2015. Nine Months Ended October 3, 2015 Expected volatility 76 % Expected dividends 0.00 % Expected term 5.7 years Risk-free rate 1.71 % The weighted average grant date fair value of options granted during the nine months ended October 3, 2015 was $0.75. As of October 3, 2015, there was approximately $2,022,000 of total unrecognized compensation expense expected to be recognized over a weighted average period of 2.38 years. Stock Award On April 16, 2015, the Company awarded 125,000 shares of the Company’s common stock that were fully vested and non-forfeitable to Mark Germain, who resigned from the Board. These shares were granted as compensation for his services as a director of the Company through April 16, 2015. The fair value of the award, which amounted to approximately $154,000 was based on the trading price of the Company’s stock on the date of grant. The expense related to this stock award was immediately recognized. Restricted Stock Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award. The following table summarizes activity of restricted stock awards granted to employees at October 3, 2015 and changes during the nine months then ended: Weighted Average Award-Date Shares Fair Value Unvested shares at January 3, 2015 1,590,000 $ 1.18 Granted - - Vested (520,000 ) 1.41 Forfeited - - Unvested shares at October 3, 2015 1,070,000 $ 1.07 Expected to Vest as of October 3, 2015 1,070,000 $ 1.07 On February 25, 2015, Michael Brauser and Barry Honig, then members of the Company’s Board of Directors (the “Board”), resigned from the Board. In connection with these resignations, the Board authorized the immediate vesting, as of the date of the resignations, of 250,000 shares of unvested restricted stock held by Mr. Brauser and 250,000 shares of unvested restricted stock held by Mr. Honig. The expense for this vested restricted stock was recognized during the fiscal year ended January 3, 2015. On April 16, 2015, Mark Germain, then a member of the Board, resigned from the Board. In connection with Mr. Germain’s resignation, the Board authorized the immediate vesting, as of the date of Mr. Germain’s resignation, of 10,000 shares of unvested restricted stock held by Mr. Germain. The expense for this vested restricted stock was recognized during the fiscal year ended January 3, 2015. On July 9, 2015, Glenn Halpryn, then a member of the Board, resigned from the Board. In connection with Mr. Halpryn’s resignation, the Board authorized the immediate vesting, as of the date of Mr. Halpryn’s resignation, of 10,000 shares of unvested restricted stock held by Mr. Halpryn. The expense for this vested restricted stock was recognized during the fiscal year ended January 3, 2015. Employee Option, Stock and Restricted Stock Compensation The Company recognized compensation expense of approximately $418,000 and $1,238,000 in general and administrative expenses in the statement of operations for the three and nine months ended October 3, 2015, respectively, and approximately $388,000 and $2,359,000 for the three and nine months ended September 27, 2014, respectively. 7B. Non-Employee Share-Based Compensation Stock Option Plans The following table summarizes activity of stock options granted to non-employees at October 3, 2015 and changes during the nine months then ended: Weighted Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term Value Outstanding at January 3, 2015 1,050,451 $ 1.35 5.46 Options Granted - - Options Classification from Employee to Non-Employee 1,542,071 0.93 Options Exercised - - Options Forfeited - - Outstanding at October 3, 2015 2,592,522 $ 1.10 6.29 $ 594,000 Exercisable at October 3, 2015 2,547,522 $ 1.10 6.24 $ 593,000 The aggregate intrinsic values in the table above are based on the Company’s closing stock price of $1.25 on the last day of business for the period ended October 3, 2015. As of October 3, 2015, there was approximately $31,000 of total unrecognized compensation expense expected to be recognized over a weighted average period of approximately 11 months. Stock and Restricted Stock Awards Restricted stock awards granted by the Company to non-employees generally feature time vesting service conditions, specified in the respective service agreements. Restricted stock awards issued to non-employees are accounted for at current fair value through the vesting period. On January 27, 2015, the Company awarded 350,000 shares of the Company’s common stock to non-employees. 210,000 of these shares were treated as stock awards as the shares vested immediately on the date of award, and the remaining 140,000 shares, which were initially treated as unvested restricted stock, vested on May 28, 2015. The fair values of the awards, which totaled approximately $350,000, were measured based on the trading prices of the Company’s stock on the date of award and the date vested. The expense related to these stock awards were fully recognized during the nine-month period ended October 3, 2015. In addition, 18,000 shares of restricted stock that were granted to a certain non-employee during the fiscal year ended January 3, 2015 became vested during the nine-month period ended October 3, 2015. The fair value of these vested restricted shares was approximately $22,000, which represents the market value of the Company’s common stock on respective vesting dates charged to expense. The following table summarizes activity of restricted stock awards issued to non-employees at October 3, 2015 and changes during the nine months then ended: Weighted Average Shares Fair Value Unvested shares at January 3, 2015 76,000 $ 0.90 Granted 140,000 0.86 Vested (158,000 ) 1.21 Forfeited - - Unvested shares expected to vest at October 3, 2015 58,000 $ 1.25 As of October 3, 2015, there was approximately $73,000 of total unrecognized compensation expense related to the restricted stock award to a non-employee. That cost is expected to be recognized over a period of 2.4 years as of October 3, 2015. Non-Employee Option, Stock and Restricted Stock Compensation The Company recognized share-based compensation expense of approximately $15,000 and $418,000 in general and administrative expenses in the statement of operations for the three and nine months ended October 3, 2015 and approximately $43,000 and $109,000 for the three and nine months ended September 27, 2014, respectively.

Business Segments

Business Segments	9 Months Ended
	Oct. 03, 2015
Business Segments
Note 8. Business Segments	The Company has following three reportable segments. · Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries. · Core standards, and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials, and related contract services. · Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks. The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment. Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Three months ended October 3, 2015 Ingredients segment Other Total October 3, 2015 Net sales $ 4,146,597 $ 1,875,296 $ 265,416 $ - $ 6,287,309 Cost of sales 2,157,183 1,533,402 115,094 - 3,805,679 Gross profit 1,989,414 341,894 150,322 - 2,481,630 Operating expenses: Sales and marketing 259,874 287,901 3,103 - 550,878 General and administrative - - - 1,753,622 1,753,622 Operating expenses 259,874 287,901 3,103 1,753,622 2,304,500 Operating income (loss) $ 1,729,540 $ 53,993 $ 147,219 $ (1,753,622 ) $ 177,130 Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Three months ended September 27, 2014 Ingredients segment Other Total Net sales $ 2,031,250 $ 1,814,622 $ 293,838 $ - $ 4,139,710 Cost of sales 1,200,790 1,239,356 176,618 - 2,616,764 Gross profit 830,460 575,266 117,220 - 1,522,946 Operating expenses: Sales and marketing 243,068 259,951 15,643 - 518,662 General and administrative - - - 1,651,718 1,651,718 Operating expenses 243,068 259,951 15,643 1,651,718 2,170,380 Operating income (loss) $ 587,392 $ 315,315 $ 101,577 $ (1,651,718 ) $ (647,434 ) Nine months ended October 3, 2015 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Net sales $ 10,238,574 $ 6,546,816 $ 864,270 $ - $ 17,649,660 Cost of sales 5,629,564 4,742,480 397,670 - 10,769,714 Gross profit 4,609,010 1,804,336 466,600 - 6,879,946 Operating expenses: Sales and marketing 832,779 935,237 8,387 - 1,776,403 General and administrative - - - 6,016,557 6,016,557 Operating expenses 832,779 935,237 8,387 6,016,557 7,792,960 Operating income (loss) $ 3,776,231 $ 869,099 $ 458,213 $ (6,016,557 ) $ (913,014 ) Nine months ended September 27, 2014 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Net sales $ 4,889,431 $ 5,407,455 $ 773,116 $ - $ 11,070,002 Cost of sales 2,962,505 3,728,521 472,256 - 7,163,282 Gross profit 1,926,926 1,678,934 300,860 - 3,906,720 Operating expenses: Sales and marketing 793,414 694,523 66,840 - 1,554,777 General and administrative - - - 6,458,027 6,458,027 Loss from investment in affiliate - - - 21,543 21,543 Operating expenses 793,414 694,523 66,840 6,479,570 8,034,347 Operating income (loss) $ 1,133,512 $ 984,411 $ 234,020 $ (6,479,570 ) $ (4,127,627 ) At October 3, 2015 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Total assets $ 6,527,861 $ 3,042,917 $ 110,284 $ 5,365,544 $ 15,046,606 At January 3, 2015 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Total assets $ 3,757,073 $ 3,220,518 $ 105,711 $ 4,433,545 $ 11,516,847 Disclosure of major customers During the three and nine months ended October 3, 2015, Customer B in our ingredients segment accounted for 19.1% and 13.8%, respectively of the Company’s total sales. During the three and nine months ended September 27, 2014, Customer A in our ingredients segment accounted for 12.3% and 13.8%, respectively of the Company’s total sales.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 03, 2015
Commitments and Contingencies Disclosure [Abstract]
Note 9. Commitments and Contingencies	Capitalized Lease Obligations On January 31, 2015, the Company entered into a financing transaction to purchase laboratory equipment. Under the lease terms, the Company will make monthly lease payments, including interest, of approximately $7,000 for 48 months, for a total payment of approximately $356,000. The Company has recorded a capital lease of approximately $304,000. The equipment will be utilized in our core standards and contract services segment. Inventory Purchase Obligations On September 29, 2015, the Company entered into an agreement with W.R. Grace & Co. Conn. (“Grace”) pursuant to which the Company has agreed to purchase from Grace not less than approximately $6.1 million worth of nicotinamide riboside chloride (the “Required Volume”) at a fixed price per kilogram (the “Price per Kilogram”) between September 4, 2015 and December 31, 2015. So long as Grace makes available for sale to the Company the Required Volume prior to December 31, 2015, if the Company does not in fact purchase the Required Volume the Company will be obligated to pay the Price per Kilogram for the difference in kilograms between the Required Volume and the amount actually purchased. If Grace is unable to deliver the Required Volume by December 31, 2015, it will continue to deliver nicotinamide riboside chloride until it has delivered the Required Amount and the Company will pay for amounts delivered after December 31, 2015 within 60 days after they have been delivered. As of October 3, 2015, the Company had purchased approximately $1.0 million of the $6.1 million it is required to purchase pursuant to the agreement.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Oct. 03, 2015
Related Party Transactions [Abstract]
Note 10. Related Party Transactions	On August 28, 2015, the Company entered into an Exclusive Supply Agreement (the “Supply Agreement”) with Healthspan Research, LLC (“Healthspan”). Under the terms of the Supply Agreement, Healthspan agreed to purchase NIAGEN® from the Company and the Company granted to Healthspan worldwide rights for resale of specific dietary supplements containing NIAGEN® in certain markets. Pursuant to the terms of the Supply Agreement, in exchange for a 4% equity interest in Healthspan, the Company agreed to initially supply NIAGEN® to Healthspan free of charge and thereafter at a fixed price and, in exchange for an additional 5% equity interest in Healthspan, the Company will grant to Healthspan certain exclusive rights to resell NIAGEN® in certain direct response channels. Healthspan will pay the Company royalties on the cumulative worldwide net sales of its finished products containing NIAGEN®. The exclusivity rights will remain for so long as Healthspan meets certain minimum purchase requirements. In the event that, during the initial term, the Company terminates the exclusivity rights due to failure to meet the minimum purchase requirements or for any reason other than a material breach of the Supply Agreement by Healthspan, then the 5% equity interest shall be automatically redeemed for a purchase price of $1.00 effective upon the date of termination of the exclusivity rights. In connection with the foregoing, also on August 28, 2015, the Company and Healthspan entered into an interest purchase agreement and limited liability company agreement pursuant to which the Company was issued 9% of the outstanding equity interests of Healthspan. Rob Fried, a director of the Company, is the manager of Healthspan and owns 91% of the outstanding equity interests of Healthspan. The Supply Agreement, interest purchase agreement and limited liability company agreement were unanimously approved by the independent directors of the Company. As of October 3, 2015, the Company had not shipped any NIAGEN® to Healthspan and no accounting was done for the nine-month period ended on October 3, 2015.

Subsequent Events

Subsequent Events	9 Months Ended
	Oct. 03, 2015
Subsequent Events [Abstract]
Note 11. Subsequent Events	Subsequent to the nine-month period ended October 3, 2015, the Company entered into Securities Purchase Agreements with certain existing stockholders to raise $2,000,000 in a registered direct offering. Pursuant to the SPAs, the Company sold a total of 200,000 Units at a purchase price of $10.00 per Unit, with each Unit consisting of eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years. The offering was made pursuant to a prospectus supplement dated November 4, 2015 and an accompanying prospectus dated May 8, 2015 pursuant to the Company’s shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on May 8, 2015 and became effective on June 5, 2015 (File No. 333-203204). The prospectus supplement registered the shares of common stock issued in the offering and the common stock underlying the warrants.

Significant Accounting Polici19

Significant Accounting Policies (Policy)	9 Months Ended
	Oct. 03, 2015
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation
Changes in accounting principle	Changes in accounting principle: The Company early adopted the amendments in this ASU effective as of April 4, 2015. As of October 3, 2015 and January 3, 2015, the Company had unamortized debt issuance costs of $75,264 and $91,361, respectively. The Company had previously presented the debt issuance costs as other noncurrent assets in its consolidated balance sheet as of January 3, 2015 in the Company’s Annual Report on Form 10-K filed with the Commission on March 19, 2015. The early adoption has resulted in adjustments to the Company’s consolidated balance sheet as of January 3, 2015, by reclassifying the debt issuance costs as a direct deduction from the carrying amount of the debt liability. Below are the effects of the change on the consolidated balance sheet as of January 3, 2015. ChromaDex Corporation and Subsidiaries Condensed Consolidated Balance Sheet January 3, 2015 Previously As Reported Adjustments Adjusted Assets Current Assets $ 9,898,691 $ - $ 9,898,691 Leasehold Improvements and Equipment, net 1,264,660 - 1,264,660 Other Noncurrent Assets 444,857 (91,361 ) 353,496 Total assets $ 11,608,208 $ (91,361 ) $ 11,516,847 Liabilities and Stockholders' Equity Current Liabilities $ 4,980,820 $ - $ 4,980,820 Loan payable, less current maturities, net 2,068,474 (91,361 ) 1,977,113 Capital lease obligations, less current maturities 423,015 - 423,015 Deferred rent, less current 137,508 - 137,508 Total liabilities 7,609,817 (91,361 ) 7,518,456 Total stockholders' equity 3,998,391 - 3,998,391 Total liabilities and stockholders' equity $ 11,608,208 $ (91,361 ) $ 11,516,847
Inventories	Inventories October 3, 2015 January 3, 2015 Natural product fine chemicals $ 1,695,326 $ 1,760,305 Bulk ingredients 3,163,302 2,298,036 4,858,628 4,058,341 Less valuation allowance 695,000 324,000 $ 4,163,628 $ 3,734,341

Significant Accounting Polici20

Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 03, 2015
Accounting Policies [Abstract]
Restatement	ChromaDex Corporation and Subsidiaries Condensed Consolidated Balance Sheet January 3, 2015 Previously As Reported Adjustments Adjusted Assets Current Assets $ 9,898,691 $ - $ 9,898,691 Leasehold Improvements and Equipment, net 1,264,660 - 1,264,660 Other Noncurrent Assets 444,857 (91,361 ) 353,496 Total assets $ 11,608,208 $ (91,361 ) $ 11,516,847 Liabilities and Stockholders' Equity Current Liabilities $ 4,980,820 $ - $ 4,980,820 Loan payable, less current maturities, net 2,068,474 (91,361 ) 1,977,113 Capital lease obligations, less current maturities 423,015 - 423,015 Deferred rent, less current 137,508 - 137,508 Total liabilities 7,609,817 (91,361 ) 7,518,456 Total stockholders' equity 3,998,391 - 3,998,391 Total liabilities and stockholders' equity $ 11,608,208 $ (91,361 ) $ 11,516,847
Inventories	October 3, 2015 January 3, 2015 Natural product fine chemicals $ 1,695,326 $ 1,760,305 Bulk ingredients 3,163,302 2,298,036 4,858,628 4,058,341 Less valuation allowance 695,000 324,000 $ 4,163,628 $ 3,734,341

Loss Per Share Applicable to 21

Loss Per Share Applicable to Common Stockholders (Tables)	9 Months Ended
	Oct. 03, 2015
Loss Per Share Applicable To Common Stockholders Tables
Loss per share amounts applicable to common stockholders	Three Months Ended Nine Months Ended Oct. 3, 2015 Sept. 27, 2014 Oct. 3, 2015 Sept. 27, 2014 Net loss $ (3,716 ) $ (659,653 ) $ (1,344,423 ) $ (4,160,811 ) Basic and diluted loss per common share $ (0.00 ) $ (0.01 ) $ (0.01 ) $ (0.04 ) Weighted average common shares outstanding (1): 107,442,916 106,610,400 107,350,469 106,290,782 Potentially dilutive securities (2): Stock options 15,839,603 13,890,766 15,839,603 13,890,766 Warrants 469,020 - 469,020 - Convertible Debt 773,395 - 773,395 - (1) Includes 1,132,241 and 1,676,175 weighted average nonvested shares of restricted stock for the three months ended October 3, 2015 and September 27, 2014, respectively, and 1,305,605 and 1,606,380 weighted average nonvested shares of restricted stock for the nine months ended October 3, 2015 and September 27, 2014, respectively, which are participating securities that feature voting and dividend rights. (2) Excluded from the computation of loss per share as their impact is antidilutive.

Leasehold Improvements and Eq22

Leasehold Improvements and Equipment (Tables)	9 Months Ended
	Oct. 03, 2015
Leasehold Improvements And Equipment
Leasehold improvements and equipment	October 3, 2015 January 3, 2015 Laboratory equipment $ 3,577,132 $ 3,151,748 Leasehold improvements 513,453 495,240 Computer equipment 379,806 329,737 Furniture and fixtures 15,678 13,039 Office equipment 21,547 7,877 Construction in progress 21,561 68,141 4,529,177 4,065,782 Less accumulated depreciation 2,947,216 2,801,122 $ 1,581,961 $ 1,264,660

Loan Payable (Tables)

Loan Payable (Tables)	9 Months Ended
	Oct. 03, 2015
Debt Disclosure [Abstract]
Loan payable	Principal amount payable for following years ending December 2015 $ - 2016 905,393 2017 1,945,650 2018 2,148,957 Total principal payments 5,000,000 Accrued end of term charge 49,551 Total loan payable 5,049,551 Less unamortized debt issuance costs and debt discount 224,300 Less current portion 598,837 Loan payable – long term $ 4,226,414

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Oct. 03, 2015
Share-based Compensation Tables
Service Period Based Stock Options	Weighted Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term Value Outstanding at January 3, 2015 12,723,601 $ 1.13 7.00 Options Granted 2,051,685 1.22 10.00 Options Classification from Employee to Non-Employee (1,542,071 ) 0.93 Options Exercised (35,548 ) 0.71 Options Forfeited (150,586 ) 1.16 Outstanding at October 3, 2015 13,047,081 $ 1.17 6.64 $ 2,389,000 Exercisable at October 3, 2015 9,793,365 $ 1.16 5.84 $ 2,061,000
Weighted average assumptions of stock options granted	Nine Months Ended October 3, 2015 Expected volatility 76 % Expected dividends 0.00 % Expected term 5.7 years Risk-free rate 1.71 %
Restricted stock awards granted to employees	Weighted Average Award-Date Shares Fair Value Unvested shares at January 3, 2015 1,590,000 $ 1.18 Granted - - Vested (520,000 ) 1.41 Forfeited - - Unvested shares at October 3, 2015 1,070,000 $ 1.07 Expected to Vest as of October 3, 2015 1,070,000 $ 1.07
Non-Employee stock options	Weighted Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term Value Outstanding at January 3, 2015 1,050,451 $ 1.35 5.46 Options Granted - - Options Classification from Employee to Non-Employee 1,542,071 0.93 Options Exercised - - Options Forfeited - - Outstanding at October 3, 2015 2,592,522 $ 1.10 6.29 $ 594,000 Exercisable at October 3, 2015 2,547,522 $ 1.10 6.24 $ 593,000
Restricted stock awards granted to non-employees	Weighted Average Shares Fair Value Unvested shares at January 3, 2015 76,000 $ 0.90 Granted 140,000 0.86 Vested (158,000 ) 1.21 Forfeited - - Unvested shares expected to vest at October 3, 2015 58,000 $ 1.25

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Oct. 03, 2015
Business Segments Tables
Business Segmentation	Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Three months ended October 3, 2015 Ingredients segment Other Total Net sales $ 4,146,597 $ 1,875,296 $ 265,416 $ - $ 6,287,309 Cost of sales 2,157,183 1,533,402 115,094 - 3,805,679 Gross profit 1,989,414 341,894 150,322 - 2,481,630 Operating expenses: Sales and marketing 259,874 287,901 3,103 - 550,878 General and administrative - - - 1,753,622 1,753,622 Operating expenses 259,874 287,901 3,103 1,753,622 2,304,500 Operating income (loss) $ 1,729,540 $ 53,993 $ 147,219 $ (1,753,622 ) $ 177,130 Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Three months ended September 27, 2014 Ingredients segment Other Total Net sales $ 2,031,250 $ 1,814,622 $ 293,838 $ - $ 4,139,710 Cost of sales 1,200,790 1,239,356 176,618 - 2,616,764 Gross profit 830,460 575,266 117,220 - 1,522,946 Operating expenses: Sales and marketing 243,068 259,951 15,643 - 518,662 General and administrative - - - 1,651,718 1,651,718 Operating expenses 243,068 259,951 15,643 1,651,718 2,170,380 Operating income (loss) $ 587,392 $ 315,315 $ 101,577 $ (1,651,718 ) $ (647,434 ) Nine months ended October 3, 2015 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Net sales $ 10,238,574 $ 6,546,816 $ 864,270 $ - $ 17,649,660 Cost of sales 5,629,564 4,742,480 397,670 - 10,769,714 Gross profit 4,609,010 1,804,336 466,600 - 6,879,946 Operating expenses: Sales and marketing 832,779 935,237 8,387 - 1,776,403 General and administrative - - - 6,016,557 6,016,557 Operating expenses 832,779 935,237 8,387 6,016,557 7,792,960 Operating income (loss) $ 3,776,231 $ 869,099 $ 458,213 $ (6,016,557 ) $ (913,014 ) Nine months ended September 27, 2014 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Net sales $ 4,889,431 $ 5,407,455 $ 773,116 $ - $ 11,070,002 Cost of sales 2,962,505 3,728,521 472,256 - 7,163,282 Gross profit 1,926,926 1,678,934 300,860 - 3,906,720 Operating expenses: Sales and marketing 793,414 694,523 66,840 - 1,554,777 General and administrative - - - 6,458,027 6,458,027 Loss from investment in affiliate - - - 21,543 21,543 Operating expenses 793,414 694,523 66,840 6,479,570 8,034,347 Operating income (loss) $ 1,133,512 $ 984,411 $ 234,020 $ (6,479,570 ) $ (4,127,627 ) At October 3, 2015 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Total assets $ 6,527,861 $ 3,042,917 $ 110,284 $ 5,365,544 $ 15,046,606 At January 3, 2015 Ingredients segment Core Standards and Contract Services segment Scientific and Regulatory Consulting segment Other Total Total assets $ 3,757,073 $ 3,220,518 $ 105,711 $ 4,433,545 $ 11,516,847

Nature of Business and Liquid26

Nature of Business and Liquidity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended
	Nov. 11, 2015	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014	Jan. 03, 2015
Liquidity
Operating income (loss)		$ 177,130			$ (647,434)	$ (913,014)	$ (4,127,627)
Net (loss)		(3,716)	$ (315,192)	$ (1,025,515)	(659,653)	(1,344,423)	(4,160,811)
Cash and cash equivalents		$ 4,708,642			$ 1,203,758	$ 4,708,642	$ 1,203,758	$ 3,964,750
Proceeds from registered direct offering	$ 2,000,000
Capital Units [Member]
Liquidity
Units sold	200,000
Purchase price per unit sold	$ 10
Unit description	Eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years.
Unit warrant exercise price	$ 1.50
Unit warrant term	3 years

Significant Accounting Polici27

Significant Accounting Policies (Details) - USD ($)	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Jan. 03, 2015
Assets
Current assets	$ 13,034,280			$ 9,898,691
Leasehold Improvements and Equipment, net	1,581,961			1,264,660
Other noncurrent assets				353,496
Total assets	15,046,606			11,516,847
Liabilities and Stockholders' Equity
Current liabilities	5,880,865			4,980,820
Loan payable, less current maturities, net	4,226,414			1,977,113
Capital lease obligations, less current maturities	500,128			423,015
Deferred rent, less current	103,461			137,508
Total liabilities	10,710,868			7,518,456
Total stockholders' equity	4,335,738	$ 3,896,462	$ 3,688,785	3,998,391
Total liabilities and stockholders' equity	$ 15,046,606			11,516,847
Scenario, Previously Reported [Member]
Assets
Current assets				9,898,691
Leasehold Improvements and Equipment, net				1,264,660
Other noncurrent assets				444,857
Total assets				11,608,208
Liabilities and Stockholders' Equity
Current liabilities				4,980,820
Loan payable, less current maturities, net				2,068,474
Capital lease obligations, less current maturities				423,015
Deferred rent, less current				137,508
Total liabilities				7,609,817
Total stockholders' equity				3,998,391
Total liabilities and stockholders' equity				$ 11,608,208
Restatement Adjustment [Member]
Assets
Current assets
Leasehold Improvements and Equipment, net
Other noncurrent assets				$ (91,361)
Total assets				$ (91,361)
Liabilities and Stockholders' Equity
Current liabilities
Loan payable, less current maturities, net				$ (91,361)
Capital lease obligations, less current maturities
Deferred rent, less current
Total liabilities				$ (91,361)
Total stockholders' equity
Total liabilities and stockholders' equity				$ (91,361)

Significant Accounting Polici28

Significant Accounting Policies (Details 1) - USD ($)	Oct. 03, 2015	Jan. 03, 2015
Inventories
Natural product fine chemicals	$ 1,695,326	$ 1,760,305
Bulk ingredients	3,163,302	2,298,036
Inventory-gross	4,858,628	4,058,341
Less valuation allowance	695,000	324,000
Inventory-net	$ 4,163,628	$ 3,734,341

Significant Accounting Polici29

Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Oct. 03, 2015	Jan. 03, 2015
Significant Accounting Policies Details Narrative
Fiscal year end	--01-02
Unamortized debt issuance costs	$ 75,264	$ 91,361

Loss Per Share Applicable to 30

Loss Per Share Applicable to Common Stockholders (Details) - USD ($)		3 Months Ended				9 Months Ended
		Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014
Net loss		$ (3,716)	$ (315,192)	$ (1,025,515)	$ (659,653)	$ (1,344,423)	$ (4,160,811)
Earnings per share
Basic and diluted loss per common share		$ 0			$ (.01)	$ (0.01)	$ (0.04)
Weighted average common shares outstanding	[1]	107,442,916			106,610,400	107,350,469	106,290,782
Stock Option [Member]
Earnings per share
Potentially dilutive securities	[2]	15,839,603			13,890,766	15,839,603	13,890,766
Warrant [Member]
Earnings per share
Potentially dilutive securities	[2]	469,020				469,020
Convertible Debt [Member]
Earnings per share
Potentially dilutive securities	[2]	773,395				773,395
[1]	Includes 1,132,241 and 1,676,175 weighted average nonvested shares of restricted stock for the three months ended October 3, 2015 and September 27, 2014, respectively, and 1,305,605 and 1,606,380 weighted average nonvested shares of restricted stock for the nine months ended October 3, 2015 and September 27, 2014, respectively, which are participating securities that feature voting and dividend rights.
[2]	Excluded from the computation of loss per share as their impact is antidilutive.

Loss Per Share Applicable to 31

Loss Per Share Applicable to Common Stockholders (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Oct. 03, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014
Loss Per Share Applicable To Common Stockholders Details Narrative
Weighted average nonvested shares of restricted stock	1,132,241	1,676,175	1,305,605	1,606,380

Leasehold Improvements and Eq32

Leasehold Improvements and Equipment (Details) - USD ($)	Oct. 03, 2015	Jan. 03, 2015
Leasehold improvements and equipment
Laboratory equipment	$ 3,577,132	$ 3,151,748
Leasehold improvements	513,453	495,240
Computer equipment	379,806	329,737
Furniture and fixtures	15,678	13,039
Office equipment	21,547	7,877
Construction in progress	21,561	68,141
Leasehold improvements and equipment, gross	4,529,177	4,065,782
Less accumulated depreciation	2,947,216	2,801,122
Leasehold improvements and equipment, total	$ 1,581,961	$ 1,264,660

Leasehold Improvements and Eq33

Leasehold Improvements and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Oct. 03, 2015	Sep. 27, 2014
Leasehold Improvements And Equipment Details Narrative
Depreciation expense on leasehold improvements and equipment	$ 209,754	$ 161,712
Disposal of equipment	$ 8,181	$ 56,110

Loan Payable - Loan payable (De

Loan Payable - Loan payable (Details) - USD ($)	Oct. 03, 2015	Jan. 03, 2015
Principal amount payable for following years ending December
2,015
2,016	$ 905,393
2,017	1,945,650
2,018	2,148,957
Total principal payments	5,000,000
Accrued end of term charge	49,551
Total loan payable	5,049,551
Less unamortized debt issuance costs and debt discount	224,300
Less current portion	598,837	$ 223,358
Loan payable – long term	$ 4,226,414	$ 1,977,113

Loan Payable (Details Narrative

Loan Payable (Details Narrative)	3 Months Ended	9 Months Ended
	Oct. 03, 2015USD ($)	Oct. 03, 2015USD ($)
Debt Disclosure [Abstract]
Term loan	$ 5,000,000	$ 5,000,000
Funded at closing on September 29, 2014	2,500,000	2,500,000
Remaining available drawn on June 18, 2015	2,500,000	$ 2,500,000
Maturity date		Apr. 1, 2018
Interest-only period extended to		Mar. 31, 2016
Interest-only period extended to if revenue milestone hit		Jun. 30, 2016
Facility fee		$ 15,000
End of term charge	93,750	$ 93,750
End of term charge rate		3.75%
Revenue milestone		Pursuant to the Amendment, the parties agreed that the interest only period shall be extended to March 31, 2016, provided however that if the Company’s consolidated revenue is equal to or greater than $11.5 million for the six months ending December 31, 2015, then the interest-only period shall be extended to June 30, 2016.
Interest expenses	$ 166,000	$ 387,000

Share-Based Compensation - Empl

Share-Based Compensation - Employees Service Based (Details)	9 Months Ended
	Oct. 03, 2015USD ($)$ / sharesshares
Number of Shares
Outstanding at Beginning of Period | shares	12,723,601
Options Granted | shares	2,051,685
Options Classification from Employee to Non-Employee | $	$ (1,542,071)
Options Exercised | shares	(35,548)
Options Forfeited | shares	(150,586)
Outstanding at End of Period | shares	13,047,081
Exercisable at End of Period | shares	9,793,365
Weighted Average Exercise Price
Outstanding at Beginning of Period	$ 1.13
Options Granted	1.22
Options Classification from Employee to Non-Employee	0.93
Options Exercised	.71
Options Forfeited	1.16
Outstanding at End of Period	1.17
Exercisable at End of Period	$ 1.16
Weighted Average Remaining Contractual Term
Outstanding at Beginning of Period	7 years
Options Granted	10 years
Outstanding at End of Period	6 years 7 months 9 days
Exercisable at End of Period	5 years 10 months 2 days
Aggregate Intrinsic Value
Outstanding at End of Period | $	$ 2,389,000
Exercisable at End of Period | $	$ 2,061,000

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions (Details 1)	9 Months Ended
	Oct. 03, 2015
Weighted average assumptions for options granted to employees
Expected volatility	76.00%
Expected dividends	0.00%
Expected term	5 years 8 months 12 days
Risk-free rate	1.71%

Share-Based Compensation - Em38

Share-Based Compensation - Employees - Restricted Stock (Details 2) - Restricted Stock [Member]	9 Months Ended
	Oct. 03, 2015$ / sharesshares
Summary of activity of restricted stock awards granted to employees- Shares
Unvested shares at Beginning of Period	1,590,000
Granted
Vested	(520,000)
Forfeited
Unvested shares at End of Period	1,070,000
Expected to Vest as of End of Period	1,070,000
Weighted Average Award-Date Fair Value
Unvested shares at Beginning of Period | $ / shares	$ 1.18
Granted | $ / shares
Vested | $ / shares	$ 1.41
Forfeited | $ / shares
Unvested shares at End of Period | $ / shares	$ 1.07
Expected to Vest as of End of Period | $ / shares	$ 1.07

Share-Based Compensation - NonE

Share-Based Compensation - NonEmployee (Details 3)	9 Months Ended
	Oct. 03, 2015USD ($)$ / sharesshares
Non-Employee Share-Based Compensation- Options
Outstanding at Beginning of Period	1,050,451
Options Granted
Options Classification from Employee to Non-Employee	1,542,071
Options Exercised
Options Forfeited
Outstanding at End of Period	2,592,522
Exercisable at End of Period	2,547,522
Weighted Average Exercise Price
Outstanding at Beginning of Period | $ / shares	$ 1.35
Options Granted | $ / shares
Options Classification from Employee to Non-Employee | $ / shares	$ .93
Options Exercised | $ / shares
Options Forfeited | $ / shares
Outstanding at End of Period | $ / shares	$ 1.10
Exercisable at End of Period | $ / shares	$ 1.10
Weighted Average Remaining Contractual Term
Outstanding at Beginning of Period	5 years 5 months 15 days
Outstanding at End of Period	6 years 3 months 14 days
Exercisable at End of Period	6 years 2 months 26 days
Aggregate Intrinsic Value
Outstanding at End of Period | $	$ 594,000
Exercisable at End of Period | $	$ 593,000

Share-Based Compensation - Rest

Share-Based Compensation - Restricted Stock (Details 4) - NonEmployee Restricted Stock [Member]	9 Months Ended
	Oct. 03, 2015$ / sharesshares
Unvested shares at Beginning of Period	76,000
Granted	140,000
Vested	(158,000)
Forfeited
Unvested shares expected to vest at End of Period	58,000
Weighted Average Award-Date Fair Value
Unvested shares at Beginning of Period | $ / shares	$ 0.90
Granted | $ / shares	.86
Vested | $ / shares	$ 1.21
Forfeited | $ / shares
Unvested shares at End of Period | $ / shares	$ 1.25

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 03, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014
NonEmployee2 [Member]
Shares vested			18,000
Brauser [Member]
Shares vested			250,000
Honig [Member]
Shares vested			250,000
Germain [Member]
Shares vested			10,000
Halpryn [Member]
Shares vested			10,000
Employee Comp [Member]
Weighted average fair value of options granted			$ .75
Closing stock price	$ 1.25		$ 1.25
Unrecognized stock option expense	$ 2,022,000		$ 2,022,000
Period of stock option expense expected to be recognized over			2 years 4 months 17 days
General and administrative expenses	$ 418,000	$ 388,000	$ 1,238,000	$ 2,359,000
Employee Comp [Member] | Former Director [Member]
Common stock shares awarded, shares			125,000
Fair value of stock award			$ 154,000
NonEmployee Comp [Member]
Closing stock price	$ 1.25		$ 1.25
Unrecognized stock option expense	$ 31,000		$ 31,000
Period of stock option expense expected to be recognized over			11 months
General and administrative expenses	$ 15,000	$ 43,000	$ 418,000	$ 109,000
Common stock shares awarded, shares			350,000
Fair value of stock award			$ 350,000
Common stock shares awarded fully vested, shares	210,000		210,000
Unrecognized expense related to restricted stock awards	$ 73,000		$ 73,000
Restricted Stock award, period of expense expected to be recognized over			2 years 4 months 24 days
Fair value of vested restricted stock awards			$ 22,000
Shares vested			140,000

Business Segments (Details)

Business Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 03, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014	Jan. 03, 2015
Business Segmentation
Net sales	$ 6,287,309	$ 4,139,710	$ 17,649,660	$ 11,070,002
Cost of sales	3,805,679	2,616,764	10,769,714	7,163,282
Gross profit	2,481,630	1,522,946	6,879,946	3,906,720
Operating expenses:
Sales and marketing	550,878	518,662	1,776,403	1,554,777
General and administrative	1,753,622	1,651,718	6,016,557	6,458,027
Loss from investment in affiliate				21,543
Operating expenses	2,304,500	2,170,380	7,792,960	8,034,347
Operating income (loss)	177,130	(647,434)	(913,014)	(4,127,627)
Assets	15,046,606		15,046,606		$ 11,516,847
Ingredients Segment [Member]
Business Segmentation
Net sales	4,146,597	2,031,250	10,238,574	4,889,431
Cost of sales	2,157,183	1,200,790	5,629,564	2,962,505
Gross profit	1,989,414	830,460	4,609,010	1,926,926
Operating expenses:
Sales and marketing	$ 259,874	$ 243,068	$ 832,779	$ 793,414
General and administrative
Loss from investment in affiliate
Operating expenses	$ 259,874	$ 243,068	$ 832,779	$ 793,414
Operating income (loss)	1,729,540	587,392	3,776,231	1,133,512
Assets	6,527,861		6,527,861		3,757,073
CoreStandardsContractServices [Member]
Business Segmentation
Net sales	1,875,296	1,814,622	6,546,816	5,407,455
Cost of sales	1,533,402	1,239,356	4,742,480	3,728,521
Gross profit	341,894	575,266	1,804,336	1,678,934
Operating expenses:
Sales and marketing	$ 287,901	$ 259,951	$ 935,237	$ 694,523
General and administrative
Loss from investment in affiliate
Operating expenses	$ 287,901	$ 259,951	$ 935,237	$ 694,523
Operating income (loss)	53,993	315,315	869,099	984,411
Assets	3,042,917		3,042,917		3,220,518
Regulatory Consulting [Member]
Business Segmentation
Net sales	265,416	293,838	864,270	773,116
Cost of sales	115,094	176,618	397,670	472,256
Gross profit	150,322	117,220	466,600	300,860
Operating expenses:
Sales and marketing	$ 3,103	$ 15,643	$ 8,387	$ 66,840
General and administrative
Loss from investment in affiliate
Operating expenses	$ 3,103	$ 15,643	$ 8,387	$ 66,840
Operating income (loss)	147,219	$ 101,577	458,213	$ 234,020
Assets	$ 110,284		$ 110,284		105,711
Other Segment [Member]
Business Segmentation
Net sales
Cost of sales
Gross profit
Operating expenses:
Sales and marketing
General and administrative	$ 1,753,622	$ 1,651,718	$ 6,016,557	$ 6,458,027
Loss from investment in affiliate				21,543
Operating expenses	1,753,622	1,651,718	6,016,557	6,479,570
Operating income (loss)	(1,753,622)	$ (1,651,718)	(6,016,557)	$ (6,479,570)
Assets	$ 5,365,544		$ 5,365,544		$ 4,433,545

Business Segments (Details Narr

Business Segments (Details Narrative) - Ingredients Segment [Member]	3 Months Ended		9 Months Ended
	Oct. 03, 2015	Sep. 27, 2014	Oct. 03, 2015	Sep. 27, 2014
Customer B [Member]
Customer concentration risk	19.10%		13.80%
Customer A [Member]
Customer concentration risk		12.30%		13.80%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	9 Months Ended
	Oct. 03, 2015USD ($)
Inventory Purchase Commitment [Member]
Purchase commitment	$ 6,100,000
Purchase commitment terms	So long as Grace makes available for sale to the Company the Required Volume prior to December 31, 2015, if the Company does not in fact purchase the Required Volume the Company will be obligated to pay the Price per Kilogram for the difference in kilograms between the Required Volume and the amount actually purchased. If Grace is unable to deliver the Required Volume by December 31, 2015, it will continue to deliver nicotinamide riboside chloride until it has delivered the Required Amount and the Company will pay for amounts delivered after December 31, 2015 within 60 days after they have been delivered.
Inventory purchased	$ 1,000,000
Capital Lease Obligations [Member]
Monthly lease payment	$ 7,000
Capital lease term	48 months
Capital lease future payments	$ 356,000
Capital lease	$ 304,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Related Party [Member]	9 Months Ended
	Oct. 03, 2015
Related party transaction description	Pursuant to the terms of the Supply Agreement, in exchange for a 4% equity interest in Healthspan, the Company will initially supply NIAGEN® to Healthspan free of charge and thereafter at a fixed price and, in exchange for a 5% equity interest in Healthspan, the Company will grant to Healthspan certain exclusive rights to resell NIAGEN® in certain direct response channels. Healthspan will pay the Company royalties on the cumulative worldwide net sales of its finished products containing NIAGEN®. The exclusivity rights will remain for so long as Healthspan meets certain minimum purchase requirements.
Equity interest received	9.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	Nov. 11, 2015USD ($)$ / sharesshares
Proceeds from registered direct offering | $	$ 2,000,000
Capital Units [Member]
Units sold | shares	200,000
Purchase price per unit sold	$ 10
Unit description	Eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years.
Unit warrant exercise price	$ 1.50
Unit warrant term	3 years